Business Context and Reporting Period
This Form 8-K filing by DexCom, Inc. (DXCM) is dated December 19, 2025. The report details a significant leadership transition, confirming the appointment of Jacob S. Leach as President and Chief Executive Officer, effective January 1, 2026, following the resignation of Kevin R. Sayer. Mr. Leach had previously served as interim principal executive officer since Mr. Sayer's medical leave began in September 2025.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and governance changes.
Material Changes
The primary material change is the formalization of the CEO succession plan. Jacob S. Leach transitions from interim CEO to permanent CEO. Concurrently, the Board expects Kevin R. Sayer to return from medical leave on or about March 2026, at which point Mark Foletta will cease serving as interim Chairman.
Guidance, Outlook, and Compensation Details
Management commentary is limited to the terms of Mr. Leach's new employment agreement, effective January 1, 2026:
- Base Salary: $1,150,000 annually.
- Target Bonus: 150% of base salary.
- Restricted Stock Units (RSUs): Fair value of $7,500,000, vesting annually over three years.
- Performance Stock Units (PSUs): Target fair value of $7,500,000, subject to performance conditions.
Mr. Leach remains eligible for the Company's Severance & Change in Control Plan and standard employee benefit plans. No financial guidance or risk factors regarding operations were disclosed in this specific filing.
Investor Verification Checklist
- Verify the exact vesting schedule and performance conditions for the $7.5M PSU grant in the attached Exhibit 10.1.
- Confirm the status of Kevin R. Sayer's medical leave and the specific date of his anticipated return in March 2026.
- Review the definitive proxy statement (Schedule 14A) filed March 27, 2025, for Mr. Leach's full biographical details.
- Monitor future filings for any changes to the Board composition upon Mr. Sayer's return.